Ligand Pharma (LGND) Stock Statistics & Valuation Metrics

Ligand Pharma has a market cap or net worth of $2.17B. The enterprise value is $1.21B.

Ligand Pharma has 19,294,168 shares outstanding. The number of shares has decreased by -2.65% in one year.

Ligand Pharma’s return on equity (ROE) is >-0.01 and return on invested capital (ROIC) is 4.00%.

The current PE Ratio of Ligand Pharma is -486.05. Ligand Pharma’s PEG ratio is 1.98.

In the last 12 months, Ligand Pharma had revenue of 167.13M and earned -4.03M in profits. Earnings per share was -0.22.

In the last 12 months, operating cash flow was 52.81M and capital expenditures -17.31M, giving a free cash flow of 35.51M billion.

Ligand Pharma pays an annual dividend of $30.012, resulting in a dividend yield of ―

Ligand Pharma upcoming earnings date is Aug 11, 2025, TBA Not Confirmed.

Ligand Pharma as a current ratio of 8.93, with Debt / Equity ratio of 14.69%

In the past 12 months, Ligand Pharma has paid 6.55M in taxes.

Ligand Pharma EV to EBITDA ratio is 46.44, with an EV/FCF ratio of 19.90.

Ligand Pharma has $208.90M in cash and marketable securities with $4.45M in debt, giving a net cash position of -$204.45M billion.

Gross margin is 73.08%, with operating margin of -13.53%, and net profit margin of -2.41%.

The average price target for Ligand Pharma is $147.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy